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Comparison of P53 Mutation Status, Primary Cytoreductive Surgical 
Outcomes, and Overall Survival in Patients with Ovarian Cancer 
D Engle,1 H Fornalik,1 T Neff,1 A Button,2 K Collins,3 A Ahmed,1,4 K DeGeest,1,4 D 
Bender,1,4 S Lutgendorf,3 M Goodheart1,4 
Objective:  We examined both p53 
mutation status and primary surgical 
cytoreduction status in ovarian cancer 
patients to define possible 
characteristics associated with improved 
survival. 
Methods:  270 ovarian cancer samples 
were obtained from a large divisional 
tumor bank.   cDNA was extracted from 
stored tumor tissue, and the entire open 
reading frame (exon 2-11) was amplified 
and sequenced in both directions.  
Patients were then divided into 2 
cohorts based on p53 mutational status.  
Surgical, clinical and survival data was 
then obtained.  
Results:  Of the 270 identified patients, 
258 were evaluable for mutation status 
and clinical correlation.  160 (62%) 
patients were found to have a p53 
mutation.  Poorly differentiated tumors 
were more frequently associated with 
p53 mutations (80% vs. 67%; 
p=0.0015).  No statistically significant 
difference between stage, histology, or 
overall survival was noted between the 
2 groups.   
Optimal cytoreduction, n=162 (64%), 
was not different between mutated 
(61%) or non-mutated groups (65%; 
p=0.59).  Optimal cytoreduction was 
however, associated with a statistically 
significant better overall survival among 
both the p53 mutated (p=0.0007) and 
non-mutated patients (p=<0.0001).  In 
the p53 mutation group the median 
survival for both the optimal and 
suboptimal patients is approximately 4 
years.  While in the non-mutated group 
the median survival is 5 years for the 
optimally cytoreduced vs. 1 year for the 
suboptimal.   
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Multivariate analysis showed p53 
mutation was not predictive of survival 
for optimally cytoreduced patients 
(HR=1.315; 95%, CI 0.851-2.031).  The 
risk of death decreased in suboptimally 
cytoreduced patients with a p53 
mutation (HR=0.553; 95%, CI 0.343-
0.890).  Additionally, for those patients 
who are suboptimally cytoreduced there 
is a statistically significant difference in 
survival that favors the p53 mutation 
group (p-0.015).  
 Conclusions: Optimal surgical 
cytoreduction continues to be an 
important prognostic variable in patients 
with ovarian cancer independent of p53 
mutational status.  Among patients with 
suboptimal cytoreduction a p53 mutation 
may offer a survival advantage.    
 
 
 
